Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
12. April 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...